Literature DB >> 35675911

How I Treat IgA Nephropathy.

Heather N Reich1, Jürgen Floege2.   

Abstract

Entities:  

Keywords:  IgA nephropathy

Mesh：

Substances：

Year:  2022        PMID： 35675911      PMCID： PMC9435972          DOI： 10.2215/CJN.02710322

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   10.614


× No keyword cloud information.
  10 in total

1.  A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.

Authors:  David C Wheeler; Robert D Toto; Bergur V Stefánsson; Niels Jongs; Glenn M Chertow; Tom Greene; Fan Fan Hou; John J V McMurray; Roberto Pecoits-Filho; Ricardo Correa-Rotter; Peter Rossing; C David Sjöström; Kausik Umanath; Anna Maria Langkilde; Hiddo J L Heerspink
Journal:  Kidney Int       Date:  2021-04-18       Impact factor: 10.612

2.  Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.

Authors:  Li-Jun Liu; Ya-Zi Yang; Su-Fang Shi; Yun-Fei Bao; Chao Yang; Sai-Nan Zhu; Gui-Li Sui; Yu-Qing Chen; Ji-Cheng Lv; Hong Zhang
Journal:  Am J Kidney Dis       Date:  2019-03-25       Impact factor: 8.860

3.  Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.

Authors:  Bengt C Fellström; Jonathan Barratt; Heather Cook; Rosanna Coppo; John Feehally; Johan W de Fijter; Jürgen Floege; Gerd Hetzel; Alan G Jardine; Francesco Locatelli; Bart D Maes; Alex Mercer; Fernanda Ortiz; Manuel Praga; Søren S Sørensen; Vladimir Tesar; Lucia Del Vecchio
Journal:  Lancet       Date:  2017-03-28       Impact factor: 79.321

4.  Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis.

Authors:  A Stefanski; K G Schmidt; R Waldherr; E Ritz
Journal:  Kidney Int       Date:  1996-10       Impact factor: 10.612

5.  Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy.

Authors:  Aliza Thompson; Kevin Carroll; Lesley A Inker; Jürgen Floege; Vlado Perkovic; Sonia Boyer-Suavet; Rupert W Major; Judith I Schimpf; Jonathan Barratt; Daniel C Cattran; Barbara S Gillespie; Annamaria Kausz; Alex W Mercer; Heather N Reich; Brad H Rovin; Melissa West; Patrick H Nachman
Journal:  Clin J Am Soc Nephrol       Date:  2019-01-11       Impact factor: 8.237

6.  Evaluating a New International Risk-Prediction Tool in IgA Nephropathy.

Authors:  Sean J Barbour; Rosanna Coppo; Hong Zhang; Zhi-Hong Liu; Yusuke Suzuki; Keiichi Matsuzaki; Ritsuko Katafuchi; Lee Er; Gabriela Espino-Hernandez; S Joseph Kim; Heather N Reich; John Feehally; Daniel C Cattran
Journal:  JAMA Intern Med       Date:  2019-07-01       Impact factor: 21.873

7.  Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.

Authors:  Stephen J Nicholls; A Michael Lincoff; Michelle Garcia; Dianna Bash; Christie M Ballantyne; Philip J Barter; Michael H Davidson; John J P Kastelein; Wolfgang Koenig; Darren K McGuire; Dariush Mozaffarian; Paul M Ridker; Kausik K Ray; Brian G Katona; Anders Himmelmann; Larrye E Loss; Martin Rensfeldt; Torbjörn Lundström; Rahul Agrawal; Venu Menon; Kathy Wolski; Steven E Nissen
Journal:  JAMA       Date:  2020-12-08       Impact factor: 56.272

8.  Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

Authors:  Thomas Rauen; Frank Eitner; Christina Fitzner; Claudia Sommerer; Martin Zeier; Britta Otte; Ulf Panzer; Harm Peters; Urs Benck; Peter R Mertens; Uwe Kuhlmann; Oliver Witzke; Oliver Gross; Volker Vielhauer; Johannes F E Mann; Ralf-Dieter Hilgers; Jürgen Floege
Journal:  N Engl J Med       Date:  2015-12-03       Impact factor: 91.245

9.  Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.

Authors:  Jicheng Lv; Hong Zhang; Muh Geot Wong; Meg J Jardine; Michelle Hladunewich; Vivek Jha; Helen Monaghan; Minghui Zhao; Sean Barbour; Heather Reich; Daniel Cattran; Richard Glassock; Adeera Levin; David Wheeler; Mark Woodward; Laurent Billot; Tak Mao Chan; Zhi-Hong Liu; David W Johnson; Alan Cass; John Feehally; Jürgen Floege; Giuseppe Remuzzi; Yangfeng Wu; Rajiv Agarwal; Hai-Yan Wang; Vlado Perkovic
Journal:  JAMA       Date:  2017-08-01       Impact factor: 56.272
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.